{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gonzalez-Gonzalez A"],"funding":["Instituto de Salud Carlos III","NCI NIH HHS","Ministerio de Economía y Competitividad","National Institute of Health (US)","Instituto de Investigación Marqués de Valdecilla"],"pagination":["50"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11806587"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["<h4>Background</h4>Osteoporosis (OP), characterized by reduced bone mass and mineral density, is a global metabolic disorder that severely impacts the quality of life in affected individuals. Although current pharmacological treatments are effective, their long-term use is often associated with adverse effects, highlighting the need for safer, more sustainable therapeutic strategies. This study investigates the pro-osteogenic and anti-resorptive potential of the secretome from Smurf1-silenced mesenchymal stem cells (MSCs) as a promising cell-free therapy for bone regeneration.<h4>Methods</h4>Conditioned media (CM) from Smurf1-silenced rat (rCM-Smur1) and human MSCs (hCM-Smurf1) was collected and analyzed. Pro-osteogenic potential was assessed by measuring in vitro mineralization in human a"],"journal":["Stem cell research & therapy"],"pubmed_title":["Paracrine activity of Smurf1-silenced mesenchymal stem cells enhances bone regeneration and reduces bone loss in postmenopausal osteoporosis."],"pmcid":["PMC11806587"],"funding_grant_id":["PID2021-127493OB-C21","PREVAL 20/01","R37-CA251763","R01 CA209882","PI22/0264","PREVAL19/02","R01-CA209882","NEXT-VAL"],"pubmed_authors":["Alvarez-Iglesias I","Perez-Campo FM","Perez-Nunez MI","Alfonso-Fernandez A","Reyes R","Garcia-Sanchez D","Dotta M","Rodriguez-Rey JC","Delgado-Calle J","Diaz-Rodriguez P","Bolado-Carrancio A","Gonzalez-Gonzalez A"],"additional_accession":[]},"is_claimable":false,"name":"Paracrine activity of Smurf1-silenced mesenchymal stem cells enhances bone regeneration and reduces bone loss in postmenopausal osteoporosis.","description":"<h4>Background</h4>Osteoporosis (OP), characterized by reduced bone mass and mineral density, is a global metabolic disorder that severely impacts the quality of life in affected individuals. Although current pharmacological treatments are effective, their long-term use is often associated with adverse effects, highlighting the need for safer, more sustainable therapeutic strategies. This study investigates the pro-osteogenic and anti-resorptive potential of the secretome from Smurf1-silenced mesenchymal stem cells (MSCs) as a promising cell-free therapy for bone regeneration.<h4>Methods</h4>Conditioned media (CM) from Smurf1-silenced rat (rCM-Smur1) and human MSCs (hCM-Smurf1) was collected and analyzed. Pro-osteogenic potential was assessed by measuring in vitro mineralization in human a","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Feb","modification":"2025-04-04T02:43:33.111Z","creation":"2025-04-04T02:43:33.111Z"},"accession":"S-EPMC11806587","cross_references":{"pubmed":["39920824"],"doi":["10.1186/s13287-025-04165-0"]}}